Shares of ImmuPharma plc (LON:IMM) experienced a 5.6% decrease on Friday, with the stock trading as low as GBX 1.03 ($0.01) and last traded at GBX 1.15 ($0.01). The trading volume was approximately 845,057 shares, which is a 7% decline from the average daily volume of 911,549 shares. Previously, the stock had closed at GBX 1.22 ($0.02).
ImmuPharma's price performance shows a 50-day simple moving average of GBX 1.38 and a 200-day simple moving average of GBX 1.66. The company has a market capitalization of £5.00 million, a price-to-earnings ratio of -120.00, and a beta of 1.53.
ImmuPharma plc is a biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics for the therapy areas of autoimmunity, inflammation, and anti-infectives. The company's lead product candidate, Lupuzor, an autophagy immunomodulator, is currently in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
